Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer.
Hiroshima Y, Nakamura F, Miyamoto H, Mori R, Taniguchi K, Matsuyama R, Akiyama H, Tanaka K, Ichikawa Y, Kato S, Kobayashi N, Kubota K, Nagashima Y, Goshima Y, Endo I. Hiroshima Y, et al. Among authors: miyamoto h. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S369-78. doi: 10.1245/s10434-012-2491-3. Epub 2012 Jul 18. Ann Surg Oncol. 2013. PMID: 22805864
A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, Katsuki S, Hirayama M, Takahashi M, Ono M, Maeda M, Takada K, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Hirata K, Kato J. Hirakawa M, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2013 Mar;71(3):789-97. doi: 10.1007/s00280-013-2073-5. Epub 2013 Jan 22. Cancer Chemother Pharmacol. 2013. PMID: 23338051 Clinical Trial.
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: miyamoto h. Gastric Cancer. 2017 May;20(3):517-526. doi: 10.1007/s10120-016-0633-1. Epub 2016 Aug 23. Gastric Cancer. 2017. PMID: 27553665 Clinical Trial.
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. Uemura N, et al. Among authors: miyamoto h. Cancer Chemother Pharmacol. 2017 Oct;80(4):707-713. doi: 10.1007/s00280-017-3404-8. Epub 2017 Aug 28. Cancer Chemother Pharmacol. 2017. PMID: 28849257 Clinical Trial.
1,911 results